AIM: To evaluate the timing of chemotherapy in gastric cancer by comparing survival outcomes in treatment groups. METHODS: Patients with surgically resected gastric adenocarcinoma from 1988 to 2006 were identified from the Los Angeles County Cancer Surveillance Program. To evaluate the population most likely to receive and/or benefit from adjunct chemotherapy, inclusion criteria consisted of Stage II or III gastric cancer patients > 18 years of age who underwent curative-intent surgical resection. Patients were categorized into three groups according to the receipt of chemotherapy: (1) no chemotherapy; (2) preoperative chemotherapy; or (3) postoperative chemotherapy. Clinical and pathologic characteristics were compared across the different treatment arms. RESULTS: Of 1518 patients with surgically resected gastric cancer, 327 (21.5%) received perioperative chemotherapy. The majority of these 327 patients were male (68%) with a mean age of 61.5 years; and they were significantly younger than non-chemotherapy patients (mean age, 70.7; P < 0.001). Most patients had tumors frequently located in the distal stomach (34.5%). Preoperative chemotherapy was administered to 11.3% of patients (n = 37) and postoperative therapy to 88.7% of patients (n = 290). An overall survival benefit according to timing of chemotherapy was not observed on univariate or multivariate analysis. Similar results were observed with stage-specific survival analyses (5-year overall survival: Stage II, 25% vs 30%, respectively; Stage III, 14% vs 11%, respectively). Therefore, our results do not identify a survival advantage for specific timing of chemotherapy in locally advanced gastric cancer. CONCLUSION: This study supports the implementation of a randomized trial comparing the timing of perioperative therapy in patients with locally advanced gastric cancer.
AIM: To evaluate the timing of chemotherapy in gastric cancer by comparing survival outcomes in treatment groups. METHODS:Patients with surgically resected gastric adenocarcinoma from 1988 to 2006 were identified from the Los Angeles County Cancer Surveillance Program. To evaluate the population most likely to receive and/or benefit from adjunct chemotherapy, inclusion criteria consisted of Stage II or III gastric cancerpatients > 18 years of age who underwent curative-intent surgical resection. Patients were categorized into three groups according to the receipt of chemotherapy: (1) no chemotherapy; (2) preoperative chemotherapy; or (3) postoperative chemotherapy. Clinical and pathologic characteristics were compared across the different treatment arms. RESULTS: Of 1518 patients with surgically resected gastric cancer, 327 (21.5%) received perioperative chemotherapy. The majority of these 327 patients were male (68%) with a mean age of 61.5 years; and they were significantly younger than non-chemotherapy patients (mean age, 70.7; P < 0.001). Most patients had tumors frequently located in the distal stomach (34.5%). Preoperative chemotherapy was administered to 11.3% of patients (n = 37) and postoperative therapy to 88.7% of patients (n = 290). An overall survival benefit according to timing of chemotherapy was not observed on univariate or multivariate analysis. Similar results were observed with stage-specific survival analyses (5-year overall survival: Stage II, 25% vs 30%, respectively; Stage III, 14% vs 11%, respectively). Therefore, our results do not identify a survival advantage for specific timing of chemotherapy in locally advanced gastric cancer. CONCLUSION: This study supports the implementation of a randomized trial comparing the timing of perioperative therapy in patients with locally advanced gastric cancer.
Authors: Kui Son Choi; Jae Kwan Jun; Hoo-Yeon Lee; Sohee Park; Kyu Won Jung; Mi Ah Han; Il Ju Choi; Eun-Cheol Park Journal: Cancer Sci Date: 2011-06-09 Impact factor: 6.716
Authors: Johan L Dikken; Edwin P M Jansen; Annemieke Cats; Berdine Bakker; Henk H Hartgrink; Elma Meershoek-Klein Kranenbarg; Henk Boot; Hein Putter; Koen C M J Peeters; Cornelis J H van de Velde; Marcel Verheij Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 44.544
Authors: Ravi Shridhar; Khaldoun Almhanna; Sarah E Hoffe; William Fulp; Jill Weber; Michael D Chuong; Kenneth L Meredith Journal: Cancer Date: 2013-01-29 Impact factor: 6.860
Authors: Gaya Spolverato; Yuhree Kim; Aslam Ejaz; Vicente Valero; Malcolm H Squires; George Poultsides; Ryan C Fields; Mark Bloomston; Sharon M Weber; Alexandra W Acher; Konstantinos Votanopoulos; Carl Schmidt; Clifford S Cho; Shishir K Maithel; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2014-06-10 Impact factor: 3.452
Authors: Yoontaek Lee; Sa-Hong Min; Ki Bum Park; Young Suk Park; Ji-Won Kim; Sang-Hoon Ahn; Jin Won Kim; Do Joong Park; Keun-Wook Lee; Hyung-Ho Kim Journal: J Gastric Cancer Date: 2018-03-20 Impact factor: 3.720